Amlodipine Does Not Require Tapering for Discontinuation
Amlodipine can be discontinued abruptly without tapering in most patients, as there is no evidence of rebound hypertension or withdrawal phenomena with this calcium channel blocker. This is fundamentally different from medications like beta-blockers or clonidine, which require gradual dose reduction.
Why Tapering Is Not Necessary
The pharmacokinetic profile of amlodipine makes tapering unnecessary. With an elimination half-life of 40-60 hours, the drug naturally tapers itself over 7-10 days after discontinuation 1. When treatment is stopped, blood pressure returns gradually to baseline over this period without rebound effects 1. This extended half-life creates a built-in "auto-taper" that prevents the abrupt physiological changes seen with shorter-acting medications.
Evidence from Guidelines and Drug Labels
The FDA-approved prescribing information for amlodipine contains no warnings or recommendations regarding tapering 2. Multiple cardiovascular guidelines, including those for hypertension management 3, heart failure 4, and pediatric hypertension 5, discuss amlodipine extensively but provide no tapering protocols—a notable omission that would be present if tapering were clinically necessary.
In the CAMELOT study of over 1,300 patients with coronary artery disease, amlodipine was studied without any mention of tapering requirements 2. Similarly, in heart failure trials (PRAISE studies), amlodipine discontinuation occurred without tapering protocols 2.
Clinical Approach to Discontinuation
When discontinuing amlodipine:
- Stop the medication immediately at the current dose
- Monitor blood pressure over the subsequent 7-10 days as levels gradually return to baseline
- Initiate alternative antihypertensive therapy on the same day if blood pressure control remains necessary, rather than waiting for amlodipine to clear
- Watch for return of anginal symptoms in patients being treated for angina, as symptom control will gradually diminish over 1-2 weeks
Important Caveats
Do not confuse amlodipine with medications that require tapering. Beta-blockers, clonidine, and other centrally-acting agents can cause severe rebound hypertension if stopped abruptly 6. The guideline on opioid tapering 6 specifically warns against abrupt cessation of clonidine due to rebound hypertension, tachycardia, and hypertonia—risks that do not apply to amlodipine.
In patients with severe hypertension or unstable angina, the concern is not withdrawal from amlodipine itself, but rather loss of therapeutic effect. These patients need immediate initiation of alternative therapy, not a tapering schedule.
For elderly or frail patients, while no tapering is required, closer blood pressure monitoring during the 7-10 day washout period is prudent, as they may be more sensitive to loss of blood pressure control 2.
The evidence is clear: amlodipine's pharmacology eliminates the need for dose tapering, and clinical practice should reflect this by allowing direct discontinuation when indicated.